問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
廖思涵
下載
2023-09-01 - 2027-12-31
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting5Sites
2019-12-01 - 2026-10-31
Participate Sites2Sites
Recruiting2Sites
2023-02-15 - 2025-06-30
Participate Sites11Sites
Recruiting10Sites
Terminated1Sites
2021-01-01 - 2026-12-31
Participate Sites3Sites
Recruiting3Sites
2019-09-01 - 2025-12-31
Participate Sites7Sites
Recruiting7Sites
2019-11-01 - 2025-02-28
Participate Sites8Sites
Recruiting8Sites
2017-01-01 - 2028-12-31
Participate Sites6Sites
Recruiting6Sites
2019-11-30 - 2026-09-30
Participate Sites9Sites
Recruiting9Sites
2019-12-20 - 2024-08-16
advanced hepatocellular carcinoma (HCC)
1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)
2019-11-30 - 2024-07-31
Advanced Hepatocellular Carcinoma
OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL
全部
